Skip to main content
SpringerLink
Log in

Hypotension After First-Dose ACE Inhibitor Administration in Heart Failure—Should Doctors Stop Worrying?

  • Editorial Board
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. The SOLVD Investigators. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.

    Google Scholar 

  2. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the North Scandinavian enalapril survival study. N Engl JMed 1987; 316: 1429-1435.

    Google Scholar 

  3. The SOLVD Investigators. Effects of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-691.

    Google Scholar 

  4. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-1355.

    Google Scholar 

  5. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999; 353: 9-13.

    Google Scholar 

  6. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007.

    Google Scholar 

  7. Packer M, Coats AJS, Fowler MB, et al. For the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure (COPERNICUS). N Engl J Med 2001; 344: 1651-1658.

    Google Scholar 

  8. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized ALdactone Evaluation Study investigators. N Engl J Med 1999; 341: 709-717.

    Google Scholar 

  9. Remme WJ, Swedberg K. On behalf of the Task Force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of heart failure. Eur Heart J 2001; 22: 1527-1560.

    Google Scholar 

  10. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-310.

    Google Scholar 

  11. Hobbs FDR, Jones MI, Allan TF, Wilson S, Tobias R. European survey of primary care physician perceptions on heart failure diagnosis and management (EURO-HF). Eur J Cardiol 2000; 21: 1877-1887.

    Google Scholar 

  12. The Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. Increasing awareness and improving the management of heart failure in Europe: The IMPROVEMENT of HF initiative. Eur J Heart Failure 1999; 1: 139-144.

    Google Scholar 

  13. Doherty J, Marshall H, McCallum J. Angiotensin converting enzyme inhibitor prescribing patterns in patients with heart failure. Brit J Cardiol 2001; 8: 327-330.

    Google Scholar 

  14. Acute Infarction Ramipril Efficacy (AIRE) Investigators. Effects of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828.

    Google Scholar 

  15. MacFadyen RJ, Lees KR, Reid JL. Differences in firstdose response to angiotensin converting enzyme inhibition in congestive heart failure: A placebo-controlled study. Br Heart J 1991; 66: 206-211.

    Google Scholar 

  16. Squire IB, MacFadyen RJ, Reid JL, Devlin A, Lees KR. Differing early blood pressure and renin angiotensin system responses the the first dose of angiotensin converting enzyme inhibitors in congestive heart failure. J Cardiovasc Pharmacol 1996; 27: 657-666.

    Google Scholar 

  17. Navookarasoo NT, Rahman A, Abdullah I. First dose response to angiotensin converting enzyme inhibition in congestive heart failure: A Malaysian experience. Int J Clin Pract 1999; 53: 25-30.

    Google Scholar 

  18. Vitovec J, Spinar J. First-dose hypotension after angiotensin converting enzyme (ACE) inhibitors in chronic heart failure:Acomparison of enalapril and perindopril. Eur J Heart Failure 2000; 2: 299-304.

    Google Scholar 

  19. MacFadyen RJ, Barr CS, Sturrock NDC, Fenwick M, Struthers AD. Further evidence that chronic perindopril treatment maintains neurohormonal suppression but does not lower blood pressure in chronic cardiac failure. Br J Clin Pharmacol 1997; 44: 69-76.

    Google Scholar 

  20. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sticares Cardiovascular Research Foundation, Rhoon, The Netherlands

    Willem J. Remme

Authors
  1. Willem J. Remme
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Remme, W.J. Hypotension After First-Dose ACE Inhibitor Administration in Heart Failure—Should Doctors Stop Worrying?. Cardiovasc Drugs Ther 15, 475–477 (2001). https://doi.org/10.1023/A:1013752418039

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1013752418039

Search

Navigation